Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue
Open Access
- 28 March 2026
- journal article
- review article
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (3) , e70159
Abstract
Background: Obesity and hypertension are interrelated global health challenges sharing common pathophysiological mechanisms, including insulin resistance, chronic inflammation and neurohormonal dysregulation. Emerging evidence highlights the gut microbiome as a crucial mediator in this interplay, influencing intestinal barrier integrity, systemic inflammation and metabolic homeostasis. Methods: In this narrative review, we critically examine the interplay between obesity‐induced hypertension and the gut microbiome, evaluating current evidence, therapeutic implications and future research priorities. Results: Obesity‐associated gut dysbiosis disrupts the intestinal epithelial barrier, increasing translocation of bacterial products like lipopolysaccharides into circulation, promoting systemic inflammation that exacerbates insulin resistance, adipose dysfunction and hypertension. Current treatments targeting obesity, from lifestyle modification to bariatric surgery, show beneficial effects on blood pressure, but microbiome‐targeted interventions are an evolving therapeutic frontier. Prebiotics, probiotics, synbiotics and faecal microbiota transplantation have demonstrated potential antihypertensive effects in preclinical and clinical studies, although findings are heterogeneous and require confirmation in larger randomised trials. Methodological challenges remain, including the need for advanced microbial sampling techniques beyond faecal analysis to fully capture disease‐relevant microbiota alterations. Conclusion: This review synthesises current knowledge on gut microbiome involvement in obesity‐induced hypertension, evaluates microbiome‐based therapeutic strategies and identifies critical research gaps to guide future investigations aimed at mitigating the dual pandemics of obesity and hypertension.Keywords
This publication has 126 references indexed in Scilit:
- Amelioration of Obesity‐Related Disorders in High‐Fat Diet‐Fed C57BL/6 Mice Following Fecal Microbiota Transplantation From DL‐Norvaline‐Dosed MiceMolecular Nutrition & Food Research, 2025
- The Effect of Fecal Microbiota Transplantation on Cardiometabolic Risk Factors: A Systematic Review and Meta-AnalysisClinical Therapeutics, 2023
- A Newly Synbiotic Combination Alleviates Obesity by Modulating the Gut Microbiota–Fat Axis and Inhibiting the Hepatic TLR4/NF‐κB Signaling PathwayMolecular Nutrition & Food Research, 2023
- Physiopathological mechanisms involved in the development of hypertension associated with gut dysbiosis and the effect of nutritional/pharmacological interventionsBiochemical Pharmacology, 2022
- Dietary interventions and blood pressure in overweight or obese individuals: A systematic review and meta-analysisClinical Nutrition, 2022
- Link between microbiota and hypertension: Focus on LPS/TLR4 pathway in endothelial dysfunction and vascular inflammation, and therapeutic implication of probioticsBiomedicine & Pharmacotherapy, 2021
- Effects of Fecal Microbiome Transfer in Adolescents With ObesityJAMA Network Open, 2020
- Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018JAMA, 2020
- Probiotics Prevent Dysbiosis and the Rise in Blood Pressure in Genetic Hypertension: Role of Short‐Chain Fatty AcidsMolecular Nutrition & Food Research, 2020
- Microbial Modulation of Energy Availability in the Colon Regulates Intestinal TransitCell Host & Microbe, 2013